Esperion stock holds Buy rating, $16 target from H.C. Wainwright
H.C. Wainwright maintained a positive stance on Esperion Therapeutics (NASDAQ:ESPR) shares, reaffirming a Buy rating and a price target of $16.00. According to InvestingPro data, analyst targets for ...
Esperion stock target cut to $4 by JMP Securities
JMP Securities adjusted its price target for Esperion Therapeutics (NASDAQ:ESPR) shares, lowering it to $4.00 from the previous $7.00. Currently trading at $1.86, the stock sits well below analyst ...
Esperion price target lowered to $4 from $7 at JMP Securities
JMP Securities lowered the firm’s price target on Esperion (ESPR) to $4 from $7 and keeps an Outperform rating on the shares. JMP updated its ...
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Incyte (INCY), Enanta Pharmaceuticals (ENTA) and Esperion (ESPR)
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Incyte (INCY – Research Report), Enanta Pharmaceuticals ...
Yahoo Finance21d
Esperion Therapeutics, Inc. (ESPR)
Jan. 09, 2025 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced it will host a virtual key opinion leader (KOL) event to discuss the real-world use of NEXLETOL® (bempedoic acid) ...
Pharmaceutical Technology23d
Bempedoic acid by Esperion Therapeutics for Hypercholesterolemia: Likelihood of Approval
Bempedoic acid is under clinical development by Esperion Therapeutics and currently in Phase II for Hypercholesterolemia. According to GlobalData, Phase II drugs for Hypercholesterolemia have a 57% ...
Seeking Alpha26d
Revance Therapeutics soars after Crown Labs raises offer to $3.65 a share
Revance Therapeutics (NASDAQ:RVNC) jumped 11% in premarket trading after Crown Laboratories increased its offer above Teoxane's latest bid. Crown Labs increased its offer to $3.65 a share, above ...
Investing27d
Esperion stock falls on higher operating expense forecast
Investing.com -- Shares of Esperion (NASDAQ:ESPR) Therapeutics (NASDAQ: ESPR) fell 5.8% after the company provided an update on its expected operating expenses for the fiscal year ending December 31, ...
Investing27d
Esperion stock falls on higher operating expense forecast
Investing.com -- Shares of Esperion (NASDAQ:ESPR) Therapeutics (NASDAQ: ESPR) fell 5.8% after the company provided an update on its expected operating expenses for the fiscal year ending December ...